Eli Lilly 2013 Annual Report Download - page 86
Download and view the complete annual report
Please find page 86 of the 2013 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76 -
77 -
78 -
79 -
80 -
81 -
82 -
83 -
84 -
85 -
86 -
87 -
88 -
89 -
90 -
91 -
92 -
93 -
94 -
95 -
96 -
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
 |
 |
72
72
Reclassifications Out of
Accumulated Other
Comprehensive Loss
Details about Accumulated Other
Comprehensive Loss Components
Year Ended Affected Line Item in the Consolidated
Statements of OperationsDecember 31, 2013
Amortization of defined benefit items:
Prior service benefits, net . . . . . . . . . . . . . . $ (31.9) (1)
Actuarial losses . . . . . . . . . . . . . . . . . . . . . . 515.2 (1)
Total before tax 483.3
Tax benefit (164.3)
Net of tax 319.0
Other, net of tax . . . . . . . . . . . . . . . . . . . . . . . . . (0.3) Other—net, (income) expense
Total reclassifications for the period (net of tax).$318.7
1 These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 15).
Note 18: Other–Net, (Income) Expense
Other–net, (income) expense consisted of the following:
2013 2012 2011
Income related to termination of the exenatide collaboration with
Amylin (Note 4) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ (495.4) $ (787.8) $ —
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160.1 177.8 186.0
Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (119.7) (105.0) (79.9)
Other (income) expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (63.9) 41.0 72.9
Other–net, (income) expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ (518.9) $ (674.0) $ 179.0
For the years ended December 31, 2013 and 2012, other–net, (income) expense primarily consists of income
associated with the termination of the exenatide collaboration with Amylin, including income recognized from
the transfer to Amylin of exenatide commercial rights in all markets outside the U.S. in 2013 and income
recognized from the early payment of the exenatide revenue-sharing obligation by Amylin in 2012. See Note 4
for additional information. For the year ended December 31, 2011, other–net, (income) expense primarily
consists of the impairment on acquired IPR&D assets related to liprotamase and Amyvid (Note 8) partially
offset by gains on the disposal of investment securities.